Advertisement

Organisation › Details
Valneva S.E.
Valneva is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has various clinical-stage vaccines in development including unique vaccines against Lyme disease and chikungunya. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with approximately 490 employees. *
![]() |
Start | 2013-05-28 merged |
Group | Valneva (Group) | |
Predecessor | Vivalis S.A. | |
![]() |
Industry | avian (bird) production technology (transgenic) |
Industry 2 | vaccine | |
![]() |
Person | Lingelbach, Thomas (Intercell 201106– CEO before COO before 2001– Chiron Behring) |
Person 2 | Grimaud, Franck (Vivalis 200702 CEO) | |
![]() |
Region | Nantes |
Country | France | |
Street | 6 rue Alain Bombard Campus Bio-Quest | |
City | 44800 Saint-Herblain | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | E: 501 to 1,000 (2019-12-31) |
Currency | EUR | |
Annual sales | 126,196,000 (revenues, total, consolidated (2019) 2019-12-31) | |
Profit | -1,744,000 (2019-12-31) | |
Cash | 64,439,000 (2019-12-31) | |
* Document for �About Section�: Valneva S.E.. (1/9/20). "Press Release: Valneva Expands its Commercial Operations with the Opening of its French Commercial Office". Saint-Herblain. | ||
Record changed: 2020-11-11 |
Advertisement

More documents for Valneva (Group)
- [1] Valneva S.E.. (11/10/20). "Press Release: Valneva Announces Plans for Extraordinary General Meeting to Prepare for Potential US IPO". Saint-Herblain....
- [2] Valneva S.E.. (9/8/20). "Press Release: Valneva Initiates Phase 3 Clinical Study for its Chikungunya Vaccine Candidate VLA1553". Saint-Herblain....
- [3] Valneva S.E.. (7/20/20). "Press Release: Valneva Confirms Participation in UK Government COVID-19 Vaccine Response Program". Saint-Herblain....
- [4] Valneva S.E.. (6/18/20). "Press Release: Valneva and Bavarian Nordic Announce Marketing and Distribution Partnership". Saint-Herblain....
- [5] Valneva S.E.. (4/30/20). "Press Release: Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15". Saint-Herblain & New York, NY....
- [6] Valneva S.E.. (4/22/20). "Press Release: Valneva and Dynavax Announce Collaboration to Advance Vaccine Development for COVID-19". Saint-Herblain & Emeryville, CA....
- [7] Valneva S.E.. (2/3/20). "Press Release: Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed". Saint-Herblain....
- [8] Valneva S.E.. (1/14/20). "Press Release: US DoD Exercises Option on Ixiaro Supply Contract Bringing Total Value to $70 Million". Saint-Herblain....
- [9] Valneva S.E.. (1/9/20). "Press Release: Valneva Expands its Commercial Operations with the Opening of its French Commercial Office". Saint-Herblain....
- [10] Valneva S.E.. (12/20/19). "Press Release: Valneva Completes Delisting from the Vienna Stock Exchange". Saint-Herblain....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top